December 15, 2020 -- Japan-based biopharmaceutical company AnGes has completed the acquisition of gene editing technology firm EmendoBio for $250 million.
EmendoBio is now an independent wholly owned subsidiary of AnGes and will continue business operations in New York, NY, and Tel Aviv, Israel.
EmendoBio has developed Omni technologies, a next-generation novel nuclease discovery platform and a nuclease optimization platform with protein engineering and directed evolution capabilities. The company has leveraged its highly precise technologies to expand its opportunities in genome editing-based drug development.
The acquisition of EmendoBio significantly increases AnGes' global capabilities in genetic medicines with expansions to its pipeline and platforms.
Copyright © 2020 scienceboard.net